MDA5 variants trade antiviral activity for protection from autoimmune disease

Chris Wallace[1,2,*], Rahul Singh[1,3], Yorgo Modis[1,3,*]

[1]Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, UK

[2]MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[3]Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK

*Correspondence: C.W., cew54@cam.ac.uk; Y.M., ymodis@mrc-lmb.cam.ac.uk

Keywords: Type 1 diabetes (T1D); inflammatory bowel disease (IBD); human genetic variants; Genome-wide association studies (GWAS); fitness trade-off; autoimmune disease

Running title: MDA5 variants trade T1D protection for IBD risk

Abstract

Loss-of-function variants in MDA5, a key sensor of double-stranded RNA from viruses and

retroelements, have been associated with protection from type 1 diabetes (T1D) in genome-

wide association studies (GWAS). MDA5 loss-of-function variants have also been reported to

increase the risk of inflammatory bowel disease (IBD). Whether these associations are linked or

extend to other diseases remains unclear. Here, fine-mapping analysis of four large GWAS

datasets shows that T1D-protective loss-of-function MDA5 variants also protect against

psoriasis and hypothyroidism, while increasing the risk of IBD. The degree of autoimmune

protection and IBD risk were linearly proportional. The magnitudes of the odds ratios for

autoimmune protection and IBD risk were larger for rare MDA5 variants than for common

variants, which were differentially expressed in different geographic populations. Our analysis

suggests MDA5 genetic variants offer a direct fitness trade-off between viral clearance and

autoimmune tissue damage.

Introduction

Innate immune responses must be sensitive enough to detect infection yet specific enough to

avoid activation by cellular components. A key innate immune receptor for cytosolic double-

stranded RNA (dsRNA), a potent signature of viral infection, is MDA5[1-5]. Recognition of dsRNA

by MDA5 induces a potent IFN-β response[2,3]. The ATPase activity and dsRNA binding

cooperativity of MDA5 confer the necessary sensitivity and specificity of MDA5-dsRNA

recognition[4-6]. Mutations in the gene encoding MDA5, *IFIH1*, can perturb the balance between

sensitive and specific dsRNA recognition. *IFIH1* is a hotspot for natural variants with clinical

associations. Approximately 40 gain-of-function missense variants have been associated with

interferonopathies[7-9]. These variants promote formation of MDA5 signaling complexes, including

on endogenous dsRNAs, by either increasing the RNA binding affinity of MDA5 or inhibiting its

ATP-dependent proofreading activity [5,9,10]. Loss-of-function MDA5 variants cause recurrent

infections[11], and have been reported to contribute to inflammatory bowel disease (IBD),

including ulcerative colitis and Crohn's disease[12,13]. GWAS data have also associated loss-of-

function MDA5 variants with reduced risk of developing certain autoimmune diseases, most

notably T1D[14-19]. Specifically, variants E627* (rs35744605), R843H (rs3747517), I923V

(rs35667974), and T946A (rs1990760) have been identified as T1D-protective[14-18,20,21]. The

E627* and I923V variants are rare, with allele frequencies of 1-2%, while R843H and T946A are

common. These common variants are differentially expressed in different geographic

populations. The T946A variant is present in 70-80% of Africans and Asians but only 30-50% of

Caucasians[15-18,20]. Similarly, the R843H variant is found in 70% of Asians but only 30-40% of

Caucasians and Africans[15-18,20]. Most human *IFIH1* reference sequences contain the alleles that

are most common in Asians (Ala946/His843). These coding variants inhibit the formation of

MDA5-dsRNA signaling complexes[18,22] by reducing the RNA binding affinity of MDA5 or

hyperactivating its ATPase activity[23]. Other loss-of-function variants are splice donor variants

that reduce splicing efficiency and hence mRNA levels[19].

A robust clinical link has emerged between T1D onset and recent infection with RNA

viruses, in particular coxsackieviruses and other enteroviruses[24]. T1D patients have more

frequent and persistent enterovirus infections, which precede the appearance of prediabetic

markers, including autoantibodies[25]. MDA5 recognizes RNA from *Picornaviridae*, including

enteroviruses[1,26], which have evolved mechanisms to suppress IFN-β transcription[27,28]. MDA5-

induced inflammation in the pancreas following rotavirus infection contributes to autoimmune

destruction of pancreatic β-cells[29]. Therefore, a plausible hypothesis is that MDA5-dependent

inflammation following viral infection can trigger autoimmune β-cell killing.

Gastrointestinal viral infection has also been linked to IBD onset[30]. Intestinal cells from

IBD patients harboring loss-of-function MDA5 variants had elevated viral loads and were

compromised in their ability to maintain epithelial barrier integrity upon further exposure to the

enteric virome[13]. Hence, the frequency and clinical phenotypes of MDA5 loss-of-function

variants in IBD patients suggest that MDA5 deficiency contributes to the induction of IBD[12,13],

due in part to increased exposure and susceptibility to viral infection[11,13].

Results and Discussion

Loss-of-function MDA5 variants have been associated with recurrent infection[11], T1D

protection[14-19], and IBD risk[12,13]. However, whether these associations are linked, or whether

they apply to autoimmune disease more broadly, has not been explored. We addressed these

questions by utilizing larger, more recent GWAS studies to conduct a broader, more sensitive

survey of immune-mediated disease associations involving MDA5 variants. For our analysis, we

selected GWAS datasets to maximize the likelihood of accurate fine mapping – balancing the

need for large sample size, minimizing the use of imputed genotypes, and using ancestries that

best matched the reference panel used to derive linkage disequilibrium (LD) estimates[31-34] (see

Methods). By reviewing associations with a reported lead T1D-associated variant, I923V

(rs35667974)[15] we identified psoriasis, hypothyroidism, Crohn's disease, and ulcerative colitis

as additional associated diseases. Fine-mapping analysis using GWAS summary data for these

five diseases identified four variants likely to be causally associated with a subset of the

diseases, with considerable overlap of variants between diseases (**Fig. 1, Table 1**). Two of

these variants were coding variants, I923V and T946A, and two were splice donor variants,

rs35337543 and rs35732034. All four variants were previously associated with T1D protection[14-

19].

Given the overlaps between diseases, and the small *P* values observed for fine-mapped

variants in one disease when considering another, we called associated variants by considering

marginal association at any of these variants or other known loss-of-function variants not in LD

with any of the index variants using a stringent Bonferroni correction. This identified

associations of a fifth variant, E627* (rs35744605), with psoriasis, and hypothyroidism (**Fig. 1**).

While T946A is common, the other variants are rare (allele frequency below 3%). Fine-mapping

analysis did not find evidence for causality for variants E627* and R843H (**Table 1**). However,

for E627* the lack of evidence of causality is likely due to its low allele frequency (0.7%), which

limits power in genetics studies. In contrast, association of R843H with T1D protection is likely

attributable to LD with the co-occurring causal T946A allele (r^2 = 0.60), as previously

reported[15,16,18]. Supporting these conclusions, our accompanying biochemical and structural

study of T1D-protective MDA5 variants shows that the E627* variant lacks signaling activity due

to a loss of RNA binding affinity, whereas the R843H substitution had no effect on the structural,

biochemical or signaling activities of MDA5[23].

Comparing associations across diseases, we found that all five associated variants

offered protection against T1D, psoriasis and hypothyroidism, but increased the risk of

ulcerative colitis and Crohn's disease (**Fig. 2a**). Remarkably, a strict correlation was observed

between protection and risk (**Fig. 2b**). A statistical test of proportionality (see **Methods**)

concluded that changes in risk were linearly proportional across variants (**Fig. 2c**). Additionally,

the magnitudes of the odds ratios were larger for the rare variants than for the common variants.

Thus, the rarest variant, I923V, conferred the greatest degree of T1D protection and the

greatest risk of IBD, whereas the most common variant, T946A, was associated with the least

T1D protection and IBD risk (**Fig. 2a-b**). Notably, the T946A variant, while common in all

populations, is the major allele in Asian and African populations but the minor allele in

Caucasians.

Our GWAS meta-analysis uncovers a direct correlation between protection from

autoimmune-related diseases (T1D, psoriasis and hypothyroidism) and increased risk of IBD.

The implication is that calibration of MDA5-dependent antiviral signaling offers a fundamental

fitness trade-off. Loss-of-function MDA5 variants protect from autoimmune tissue damage,

including to pancreatic β-cells leading to T1D, but increase the risk of inflammatory tissue

damage from persistent infection, including by enteric viruses in intestinal epithelia leading to

IBD. This model predicts that gain-of-function MDA5 variants protect from chronic inflammation

and IBD by ensuring infections are cleared but do so at the cost of increasing the risk of T1D

and other autoimmune diseases.

Methods

GWAS meta-analysis

GWAS summary data for a reported lead T1D-associated variant, I923V (rs35667974) were

downloaded for the following diseases: T1D (16,000 T1D cases, 25,000 controls)[31]; IBD (5,956

Crohn's disease cases, 6,968 ulcerative colitis cases, 21,770 controls)[32]; psoriasis (19,032

cases, 286,769 controls)[33]; and hypothyroidism (20,563 cases, 399,910 controls)[34]. Data were

downloaded from the GWAS catalog from the following repositories: ulcerative colitis,

https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-

GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz

(ImmunoChip); Crohn's disease,

https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-

GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz

(ImmunoChip); T1D,

https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013001-

GCST90014000/GCST90013445/GCST90013445_buildGRCh38.tsv (ImmunoChip); Psoriasis:

http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST005001-

GCST006000/GCST005527/harmonised/23143594-GCST005527-EFO_0000676.h.tsv.gz

(Meta analysis); Hypothyroidism: https://pan-ukb-us-east-

1.s3.amazonaws.com/sumstats_flat_files/categorical-20002-both_sexes-1453.tsv.bgz (genome

wide SNP chip). These studies were selected to balance the need for large studies and those

most likely to give accurate results in fine mapping – i.e. those which minimized imputation and

most closely matched the ancestry of our reference LD panel.

Alleles were aligned to the UK Biobank as a common reference. Reference LD matrices

were estimated from 40,000 European subjects from UK Biobank. Fine mapping was performed

with a variant of the Sum of Single Effects (SuSiE)[35] model, as implemented in susieR[36].

rs72871627 was selected as a tag (r^2 = 0.99) of the splice donor variant rs35337543

because rs72871627 was available in all GWAS datasets whereas rs35337543 was only

available in the T1D GWAS dataset.

Tests of proportional effects between pairs of diseases were performed across all variants in

Table X using colocPropTest [https://cran.r-project.org/package=colocPropTest] which

implements the test of proportionality as previously described[37].

Data Availability

This study is a meta-analysis of previously published data. All code to reproduce this analysis is

available at Zenodo.org [https://doi.org/10.5281/zenodo.12771481].

Competing Interests

Y.M. is a consultant for Related Sciences LLC. The remaining authors declare no competing

interests.

Author Contributions

Conceptualization, C.E.W., R.S. and Y.M.; Methodology, C.E.W.; Formal Analysis, C.E.W. and

Y.M.; Funding Acquisition, Y.M.; Project Administration, Y.M.; Software, C.E.W.; Supervision,

Y.M.; Writing – Original Draft, Y.M.; Writing – Review & Editing, C.E.W., R.S. and Y.M.

Acknowledgements

We thank Louise Modis, Tetsuo Hasegawa, and the Modis group for useful discussions. This

work was supported by the Wellcome Trust [217191/Z/19/Z to Y.M.].

References

1.   Kato H, *et al.* Differential roles of MDA5 and RIG-I helicases in the recognition of RNA

viruses. *Nature* **441**, 101-105 (2006).

2.   Peisley A, *et al.* Cooperative assembly and dynamic disassembly of MDA5 filaments for

viral dsRNA recognition. *Proc Natl Acad Sci U S A* **108**, 21010-21015 (2011).

3.   Berke IC, Modis Y. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon

binding double-stranded RNA. *EMBO J* **31**, 1714-1726 (2012).

4.   Yu Q, Qu K, Modis Y. Cryo-EM Structures of MDA5-dsRNA Filaments at Different Stages of

ATP Hydrolysis. *Mol Cell* **72**, 999-1012 e1016 (2018).

5.   Yu Q, Herrero Del Valle A, Singh R, Modis Y. MDA5 disease variant M854K prevents ATP-

dependent structural discrimination of viral and cellular RNA. *Nat Commun* **12**, 6668 (2021).

6.   Singh R, *et al.* Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA

sensing. *J Biol Chem* **300**, 105711 (2024).

7.   Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I

interferonopathies, a conceptual overview. *J Exp Med* **213**, 2527-2538 (2016).

8.   Rutsch F, *et al.* A specific IFIH1 gain-of-function mutation causes Singleton-Merten

syndrome. *Am J Hum Genet* **96**, 275-282 (2015).

9.   Rice GI*, et al.* Genetic and phenotypic spectrum associated with IFIH1 gain-of-function.

Hum Mutat **41**, 837-849 (2020).

10. Garau J*, et al.* Molecular Genetics and Interferon Signature in the Italian Aicardi Goutieres

Syndrome Cohort: Report of 12 New Cases and Literature Review. *J Clin Med* **8**, 750

(2019).

11. Lamborn IT*, et al.* Recurrent rhinovirus infections in a child with inherited MDA5 deficiency.

J Exp Med **214**, 1949-1972 (2017).

12. Cananzi M*, et al.* IFIH1 loss-of-function variants contribute to very early-onset inflammatory

bowel disease. *Hum Genet* **140**, 1299-1312 (2021).

13. Adiliaghdam F*, et al.* Human enteric viruses autonomously shape inflammatory bowel

disease phenotype through divergent innate immunomodulation. *Sci Immunol* **7**, eabn6660

(2022).

14. Smyth DJ*, et al.* A genome-wide association study of nonsynonymous SNPs identifies a

type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* **38**, 617-

619 (2006).

15. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene

implicated in antiviral responses, protect against type 1 diabetes. *Science* **324**, 387-389

(2009).

16. Liu S*, et al.* IFIH1 polymorphisms are significantly associated with type 1 diabetes and

IFIH1 gene expression in peripheral blood mononuclear cells. *Hum Mol Genet* **18**, 358-365

(2009).

17. Vasseur E*, et al.* The selective footprints of viral pressures at the human RIG-I-like receptor

family. *Hum Mol Genet* **20**, 4462-4474 (2011).

18. Gorman JA*, et al.* The A946T variant of the RNA sensor IFIH1 mediates an interferon

program that limits viral infection but increases the risk for autoimmunity. *Nat Immunol* **18**,

744-752 (2017).

19. Downes K*, et al.* Reduced expression of IFIH1 is protective for type 1 diabetes. *PLoS One*
5, (2010).

20. de Azevedo Silva J*, et al.* Meta-analysis of STAT4 and IFIH1 polymorphisms in type 1
diabetes mellitus patients with autoimmune polyglandular syndrome type III. *Genet Mol Res*
14, 17730-17738 (2015).

21. Jermendy A, Szatmari I, Korner A, Szabo AJ, Toth-Heyn P, Hermann R. Association
between interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal
variation in the onset of type 1 diabetes mellitus. *Pediatr Diabetes* **19**, 300-304 (2018).

22. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T. Identification of loss
of function mutations in human genes encoding RIG-I and MDA5: implications for
resistance to type I diabetes. *J Biol Chem* **284**, 13348-13354 (2009).

23. Singh R*, et al.* Molecular basis of pathogenesis and protection from type 1 diabetes by loss
of function MDA5 variants. *bioRxiv*, (2024).

24. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus:
systematic review and meta-analysis of observational molecular studies. *BMJ* **342**, d35
(2011).

25. Hyoty H, Taylor KW. The role of viruses in human diabetes. *Diabetologia* **45**, 1353-1361
(2002).

26. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS
mediate type I interferon responses to coxsackie B virus. *J Virol* **84**, 254-260 (2010).

27. Visser LJ*, et al.* Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule
Formation and the Induction of Type I Interferon. *J Virol* **93**, (2019).

28. Hato SV*, et al.* The mengovirus leader protein blocks interferon-alpha/beta gene
transcription and inhibits activation of interferon regulatory factor 3. *Cell Microbiol* **9**, 2921-
2930 (2007).

29. Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ. The innate immune receptor MDA5

limits rotavirus infection but promotes cell death and pancreatic inflammation. *EMBO J* **36**,

2742-2757 (2017).

30. Axelrad JE*, et al.* Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease

in a Nationwide Case-Control Study. *Clin Gastroenterol Hepatol* **17**, 1311-1322 e1317

(2019).

31. Robertson CC*, et al.* Fine-mapping, trans-ancestral and genomic analyses identify causal

variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* **53**, 962-971 (2021).

32. Liu JZ*, et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel

disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979-986

(2015).

33. Tsoi LC*, et al.* Large scale meta-analysis characterizes genetic architecture for common

psoriasis associated variants. *Nat Commun* **8**, 15382 (2017).

34. Karczewski KJ*, et al.* Pan-UK Biobank GWAS improves discovery, analysis of genetic

architecture, and resolution into ancestry-enriched effects. *bioRxiv*,

2024.2003.2013.24303864 (2024).

35. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection

in regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol*

82, 1273-1300 (2020).

36. Zou Y, Carbonetto P, Wang G, Stephens M. Fine-mapping from summary data with the

"Sum of Single Effects" model. *PLoS genetics* **18**, e1010299 (2022).

37. Wallace C. Statistical testing of shared genetic control for potentially related traits. *Genet*

Epidemiol **37**, 802-813 (2013).

Fig. 1. Manhattan plots of fine-mapped variants for five diseases. Colored circles indicate

the fine mapping sets identified, and colored text labels the most likely causal SNP in each set,

selected due its known function on MDA5. Known loss-of-function SNPs that were not in any

fine mapping set are marked with "x" and a black label. Lower right, minor allele frequency

(MAF) and function of fine-mapped SNPs.

Figure 2. GWAS meta-analysis of loss-of-function MDA5 variants. (a) Effect sizes expressed in terms of the odd ratio for selected MDA5 loss-of-function variants. ‡Because rs35337543 was only available in two GWAS datasets, rs72871627 (r^2 = 0.973) was used as a tag for rs35337543. EAF, effect allele frequency. Error bars, SEM. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 5×10^{-8} (genome-wide significance), where P is the Bonferroni-adjusted P value from marginal association analysis. CV, likely causal variant present in a credible set in fine-mapping analysis. R843H was included in fine-mapping analysis but excluded from marginal association analysis. See **Table 1**. **(b)** Odds ratio plot for variants and diseases in *(a)*. **(c)** Estimated effect sizes in hypothyroidism compared to the other diseases. Hypothyroidism was selected because it was the largest dataset for which all SNPs were available. Dashed lines, identity and negative identity lines.

Table 1. Marginal association and fine-mapping analysis results.

Variant	SNP	Location	Allele	EAF	Disease	lnOR ± std. err.	OR	P	P$_{Bonferroni}$	Causal[‡]
I923V	rs35667974	2:162268127	T>C	0.022	T1D	-0.493 ± 0.062	0.611	1.21×10^{-15}	2.91×10^{-14}	T
					Psoriasis	-0.440 ± 0.129	0.644	6.68×10^{-4}	0.0160	F
					Hypothyr.	-0.254 ± 0.038	0.776	2.98×10^{-11}	7.16×10^{-10}	T
					Crohn's	0.121 ± 0.046	1.129	8.08×10^{-3}	0.1938	F
					UC	0.276 ± 0.046	1.318	1.94×10^{-9}	4.64×10^{-8}	T
Splice1	rs35732034	2:162268086	C>T	0.010	Psoriasis	-0.693 ± 0.253	0.500	6.25×10^{-3}	0.1500	F
					T1D	-0.464 ± 0.083	0.629	2.29×10^{-8}	5.50×10^{-7}	T
					Hypothyr.	-0.230 ± 0.056	0.794	4.47×10^{-5}	1.07×10^{-3}	F
					UC	0.180 ± 0.067	1.197	7.70×10^{-3}	0.1848	F
					Crohn's	0.226 ± 0.064	1.253	4.15×10^{-4}	9.96×10^{-3}	F
Splice2*	rs72871627	2:162280432	A>G	0.015	Psoriasis	-0.541 ± 0.200	0.582	6.81×10^{-3}	0.1634	F
					T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	1.00×10^{-8}	T
					Hypothyr.	-0.253 ± 0.046	0.777	2.94×10^{-8}	7.05×10^{-7}	T
					Crohn's	0.072 ± 0.056	1.074	0.1990	1	F
					UC	0.308 ± 0.054	1.360	1.19×10^{-8}	2.85×10^{-7}	T
Splice2	rs35337543	2:162279995	C>G	0.015	T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	ND	T
					Hypothyr.	-0.236 ± 0.045	0.790	1.51×10^{-7}	ND	T
E627*	rs35744605	2:162277580	C>A	0.007	Hypothyr.	-0.273 ± 0.068	0.761	5.63×10^{-5}	1.35×10^{-3}	F
					Psoriasis	-0.210 ± 0.372	0.810	0.5717	1	F
T946A	rs1990760	2:162267541	T>C	0.389	Psoriasis	-0.192 ± 0.034	0.825	1.95×10^{-8}	4.68×10^{-7}	T
					T1D	-0.132 ± 0.013	0.876	5.57×10^{-24}	1.34×10^{-22}	T
					Hypothyr.	-0.080 ± 0.011	0.923	5.61×10^{-13}	1.35×10^{-11}	T
					Crohn's	0.053 ± 0.013	1.055	3.36×10^{-5}	8.07×10^{-4}	F
					UC	0.086 ± 0.013	1.089	1.78×10^{-10}	4.27×10^{-9}	T
R843H	rs3747517	2:162272314	C>T	0.276	T1D	-0.111 ± 0.014	0.895	2.94×10^{-15}	ND	F
					Psoriasis	-0.103 ± 0.035	0.903	3.72×10^{-3}	ND	F
					Hypothyr.	-0.068 ± 0.012	0.934	1.85×10^{-8}	ND	F
					Crohn's	0.030 ± 0.014	1.031	0.0301	ND	F
					UC	0.051 ± 0.014	1.053	3.85×10^{-4}	ND	F
N160D	rs74162075	2-162310909	T>C	0.001	Psoriasis	-2.057 ± 0.811	0.128	0.0111	0.2674	F
					Hypothyr.	-0.270 ± 0.133	0.763	0.0427	1	F

277 EAF, effect allele frequency; OR, odds ratio.
278 *rs72871627 was used as a tag of rs35337543 because the latter was not available in all GWAS
279   datasets.
280 [‡]Causality was inferred from presence of the SNP in a credible set in fine mapping analysis.
281 Dashed lines indicate that the SNPs above and below the line are in LD with each other.